期刊文献+

胃癌嗜铬蛋白A与表皮生长因子受体表达的关系及意义 被引量:1

Relationship and significance of CGA and EGFR expression in human gastric carcinoma
原文传递
导出
摘要 目的探讨胃癌嗜铬蛋白A(CGA)与表皮生长因子受体(EGFR)表达的关系及意义。方法应用免疫组织化学ABC法检测103例手术切除的标本中胃癌组织及癌旁正常组织CGA和EGFR的表达。结果胃癌组织中CGA及EGFR表达率分别为39.8%和41.7%,均明显高于癌旁正常组织的2.9%和0(P<0.01)。CGA与EGFR表达均与肿瘤组织学类型、浸润深度、TNM分期、分化程度、有无淋巴结转移及远处转移相关。胃癌组织中,CGA阳性组EGFR的表达率明显高于CGA阴性组(65.9%vs.25.8%)。CGA与EGFR表达呈正相关(r=0.498,P<0.05)。结论 CGA、EGFR在胃癌组织中高表达,两者表达相关且与胃癌的侵袭、转移有关。 Objective To investigate the relationship and significance of chromogranin A(CGA) and epidermal growth factor receptor(EGFR) expression in human gastric carcinoma.MethodsThe expressions of CGA and EGFR in gastric cancer and tumor-adjacent normal tissues were detected by immunohistochemical ABC staining method in 103 surgical specimens.Results The positive expression rates of CGA and EGFR in the gastric cancer tissues were significantly higher than those in the tumor-adjacent normal tissues(39.8% vs.2.9% and 41.7% vs.0,respectively)(P〈0.01).The expressions of CGA and EGFR in gastric cancer were correlated with the histological type,depth of invasion,TNM classification,differenciation,lymph node and distant metastasis.The expression rate of EGFR was higher in CGA positive tumor than that in CGA negative(65.9% vs.25.8%).The expression of EGFR was positively correlated with that of CGA(r=0.492,P〈0.05).ConclusionThe CGA and EGFR are higherly expressed in human gastric carcinoma,which is positively correlated each other and is related with its invasion and metastasis.
出处 《江苏医药》 CAS CSCD 北大核心 2012年第7期829-831,共3页 Jiangsu Medical Journal
关键词 胃癌 嗜铬蛋白A 表皮生长因子受体 Gastric cancer Chromogranin A Epidermal growth factor receptor
  • 相关文献

参考文献7

二级参考文献110

  • 1黄晓东,易俊林,高黎,徐国镇,金晶,杨伟志,卢泰祥,吴少雄,吴仁瑞,胡伟汉,谢伟长,韩非,高远红,高剑铭,潘建基,陈传本,朗锦义,李涛,董昱,付玉彬,樊林,李柏森,黎静,王晓怀,陈炳旭,高献书,张萍,吴湘玮,胡炳强.抗表皮生长因子受体单克隆抗体h—R3联合放疗治疗晚期鼻咽癌的Ⅱ期临床研究[J].中华肿瘤杂志,2007,29(3):197-201. 被引量:99
  • 2Cunningham D, Humblet Y, Siena S, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer[ J]. N Engl J Med, 2004,351(4) :337 - 345.
  • 3Wilke H, Glynne-Jones R, Thaler J, et al. MABEL-A large multinational study of cetuximab plus irinotecan in irinotecan resistant metastatic colorectal cancer [ J ]. J Clin Oncol, 24 (18 Suppl ) :3549.
  • 4Lenz H J, Van Cutsem E, Khambata-Ford S, et al. Multicenter phase Ⅱ and translational study of cetuximab in metastatic colorectal carcinoma refractory to irinotecan, oxaliplatin, and fluoropyrimidines[ J]. J Clin Oncol, 2006,24(30) :4914 -4921.
  • 5Jonker D J, O'Callaghan C J, Karapetis CS, et al. Cetuximab for the treatment of colorectal cancer[ J]. N Engl J Med, 2007,357 (20) :2040-2048.
  • 6Saltz LB, Lenz HJ, Kindler HL, et al. Randomized phase Ⅱ trial of cetuximab, bevacizumab, and irinotecan compared with cetuximab and bevacizumab alone in irinotecan-refractory colorectal cancer: the BOND-2 study[J]. J Clin Oncol, 2007,25(29) : 4557 -4561.
  • 7Hecht JR, Patnaik A, Berlin J,et al. Panitumumab monotherapy in patients with previously treated metastatic colorectal cancer [J]. Cancer, 2007,110(5) :980 -988.
  • 8Van Cutsem E, Peeters M,Siena S,et al. Open-label phase Ⅲ trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer[ J]. J Clin Oncot, 2007,25 (13) :1658 -1664.
  • 9Sobrero AF, Fehrenbacher L, Rivera F, et al. Randomized phase Ⅲ trial of cetuximab plus irinotecan vs. irinotecan alone for metastatic colorectal cancer in 1298 patients who have failed prior oxaliplatin-based therapy : The EPIC trial [ J/OL ]. 2007 [ 2008 - 3 -15]. http://www, medscape, com/viewarticle1560219.
  • 10Jennis A, Polikoff J, Mitchell E, et al. Erbitux (cetuximab) plus FOLFOX for colorectal cancer ( EXPLORE ) : preliminary efficacy analysis of a randomized phase Ⅲ trial[ J]. J Clin Oncol, 2005,23( 16 Suppl) :3574.

共引文献36

同被引文献8

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部